Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 0.70 |
| ▸ | EDNRA | P25101 | 13/20 | 0.65 |
| ▸ | CCR4 | P51679 | 6/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7360560 | 0.90 | ABCB11 (0.71) | ABCB11EDNRACCR4 | |
| SCHEMBL7364303 | 0.90 | ABCB11 (0.70) | ABCB11EDNRACCR4 | |
| SCHEMBL7364530 | 0.90 | ABCB11 (0.70) | ABCB11EDNRACCR4 | |
| SCHEMBL5020959 | 0.88 | ABCB11 (0.64) | ABCB11EDNRACCR4 | |
| SCHEMBL7365241 | 0.87 | ABCB11 (0.75) | ABCB11EDNRACCR4 | |
| SCHEMBL7359675 | 0.87 | ABCB11 (0.68) | ABCB11EDNRACCR4 | |
| SCHEMBL7361361 | 0.87 | ABCB11 (0.73) | ABCB11EDNRACCR4 | |
| SCHEMBL7362617 | 0.86 | ABCB11 (0.77) | ABCB11EDNRACCR4 | |
| SCHEMBL7358677 | 0.85 | ABCB11 (0.73) | ABCB11EDNRACCR4 | |
| SCHEMBL7359279 | 0.85 | ABCB11 (0.75) | ABCB11EDNRACCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120177705-A1 | COMPOSITION 064 | ASTRAZENECA AB (SE) | 2012-07-12 | — | — | US | disclosed |
| US-20120177705-A1 | COMPOSITION 064 | ASTRAZENECA AB (SE) | 2012-07-12 | — | — | US | disclosed |
| US-8168221-B2 | Composition 064 | ASTRAZENECA AB (SE) | 2012-05-01 | — | — | US | disclosed |
| US-8168221-B2 | Composition 064 | ASTRAZENECA AB (SE) | 2012-05-01 | — | — | US | disclosed |
| US-20120101109-A1 | ETHANOLAMINE SALT OF N- (3-METHOXY-5-METHYLPYRAZIN-2YL) -2- (4-[1, 3, 4-OXADIAZOLE-2-YL] PHENYL) PYRIDINE-3- SULPHONAMIDE | ASTRAZENECA AB (SE) | 2012-04-26 | — | — | US | disclosed |
| US-20120101109-A1 | ETHANOLAMINE SALT OF N- (3-METHOXY-5-METHYLPYRAZIN-2YL) -2- (4-[1, 3, 4-OXADIAZOLE-2-YL] PHENYL) PYRIDINE-3- SULPHONAMIDE | ASTRAZENECA AB (SE) | 2012-04-26 | — | — | US | disclosed |
| EP-2433620-A1 | Zibotentan Composition | AstraZeneca AB (SE) | 2012-03-28 | — | — | EP | disclosed |
| US-20090099203-A1 | COMPOSITION 064 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099203-A1 | COMPOSITION 064 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| WO-2009047565-A2 | COMPOSITION 064 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | WO | disclosed |
| US-20080221124-A1 | Ethanolamine Salt of N- (3-Methoxy-5-Methylpyrazin-2Yl) -2- (4-[1, 3, 4-Oxadiazole-2-Yl] Phenyl) Pyridine-3-Sulphonamide | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| US-20080221124-A1 | Ethanolamine Salt of N- (3-Methoxy-5-Methylpyrazin-2Yl) -2- (4-[1, 3, 4-Oxadiazole-2-Yl] Phenyl) Pyridine-3-Sulphonamide | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| WO-2007010235-A1 | ETHANOLAMINE SALT OF N- (3-METHOXY-5-METHYLPYRAZIN-2YL) -2- (4- [1 , 3 , 4-0XADIAZ0LE-2-YL] PHENYL) PYRIDINE-3- SULPHONAMIDE | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101109-A1 | ETHANOLAMINE SALT OF N- (3-METHOXY-5-METHYLPYRAZIN-2YL) -2- (4-[1, 3, 4-OXADIAZOLE-2-YL] PHENYL) PYRIDINE-3- SULPHONAMIDE | SELENOI, PNMT, SLC6A3 | ABCB11 1151/4885EDNRA 1067/4885CCR4 4114/4885 |
| US-20090099203-A1 | COMPOSITION 064 | MGAM, MAST4, MANBA | ABCB11 1077/4885EDNRA 2957/4885CCR4 656/4885 |
| US-20080221124-A1 | Ethanolamine Salt of N- (3-Methoxy-5-Methylpyrazin-2Yl) -2- (4-[1, 3, 4-Oxadiazole-2-Yl] Phenyl) Pyridine-3-Sulphonamide | SELENOI, PNMT, NNMT | ABCB11 2042/4885EDNRA 1047/4885CCR4 4013/4885 |
| US-20120177705-A1 | COMPOSITION 064 | MGAM, MAST4, MANBA | ABCB11 1077/4885EDNRA 2957/4885CCR4 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.